Creation of a patient-centric patient lay summary in the local language

Satoru Mogami, Mikiko Noyes, Rika Morita, Atsuko Shiotsuki, Toshiaki Hagi, Hiroe Hasegawa, Chikara Iida, Mina Izuchi, Fumiharu Naganeo, Junko Tanabe, Kyoko Uno, Osamu Suga, and Chikara Kikuchi
Pfizer Japan Inc., Tokyo, Japan

Correspondence to:
Satoru Mogami
Development Japan, Pfizer Japan Inc.
3-22-7 Yoyogi, Shibuya-ku, Tokyo,
Japan 151-8589
+81 90 6009 8352
satoru.mogami@pfizer.com

Abstract
Prior to this project, no patient lay summary (PLS) had ever been developed locally in Japan. In order to create a PLS that is more tailored to local patients, we attempted to develop one in and for Japanese. Such PLS was drafted based on the disclosed summary of the clinical study report. We took a composite approach in refining the PLS by researching on lay language and patient-friendly designs. At the same time, we ensured scientific accuracy through consultation with experts such as physicians and statisticians, practised diligence on regulatory and legal aspects, and incorporated patient’s voice by consulting a local patient advocacy group. We successfully created a PLS in the Japanese language for the first time, which was more patient centric than those translated from another language.

While summary results of clinical trials have commonly been posted on global websites such as clinicaltrials.gov and EU Clinical Trials Register, the European Union Clinical Trial Regulation No. 536/2014 states that sharing clinical trial results to study participants in the form of a lay language summary is also an important endeavour. In Japan so far, we have distributed patient lay summaries (PLSs) for two clinical trials, which were originally written in English and translated into Japanese by an external organisation. In order to create PLSs that are more tailored to local patients, we have pioneered creating a Japanese PLS starting from scratch.

We formed two teams: One was responsible for researching on the characteristics of lay language, developing a template, communicating with a patient group, and considering legal and regulatory aspects; the other took charge of drafting a PLS. The two teams collaborated in refining the PLS and developing a process of PLS preparation. The team members voluntarily participated in the project and were consisted of medical writers and members of the document management group.

Developing the template
To develop a patient-friendly template, we first gathered patient information materials at local hospitals and clinics and critically evaluated their designs concerning legibility and readability. We also looked for relevant guidelines and design principles. We adopted the concept of “universal design” for effective communication and in particular considered the following aspects:
- Font and style of text: We chose to use a recommended Japanese font Meiryo primarily, as it has a very clear typeface that maintains high legibility even in bold style. Also to enhance legibility, we used a font size larger than what we would normally use for regulatory documents (i.e., 12-point size was used for the main text of the PLS while 10.5-point size would normally be used for regulatory documents).
- Line spacing: Wider line spacing was used to optimise legibility and readability. This also allowed us to place a Japanese reading aid (in form of syllabic scripts) above some Kanji characters, which are similar to Chinese characters, in order to show how this text should be read. This was a part of the attempt to keep the language level equivalent to a Japanese junior high school graduate.
- Colours: In particular, a barrier-free colour scheme (see Figure 1) was studied to make sure that even patients with colour vision abnormality can appreciate the PLS without difficulty. People with colour vision abnormality have difficulty differentiating among cold colours or warm colours. For instance, it is hard for them to distinguish between red and green, purple and blue, or orange and yellow.

We adopted the concept of “universal design” for effective communication.
Page layout of text sections: Text headings and special messages such as “thank you” should be easily discernible. This also allows readers to easily navigate through the PLS. Although the primary purpose of distributing a PLS to patients is to share clinical trial results, it also provides pharmaceutical companies the opportunity to convey their appreciation of patient participation in a study.

Aside from the points suggested by the universal design concept, we believed that the appearance of the overall printed form of a PLS was also important as it is intended for persons in already stressful situations. For instance, an accompanying image in a text can appeal to viewer’s senses and stir positive emotions, which can consequently alleviate the stress associated with illness. In this case, we chose the image of dandelions (Figure 2) because it is not only a flower familiar to many, it also has a bright colour and is very resilient. It has been used as a symbol of courage in many cultures and could represent clinical trials spreading “seeds” of possibilities. Further, we made sure that the picture followed a barrier-free colour scheme (i.e., predominantly blue and yellow), and did not use brand colour or image so that it could be applied to any drug in Pfizer.

We also identified standard texts (e.g., “thank you” message, headings for an introduction, background, etc.) for the PLS and inserted them in the template as default texts. Moreover, we followed the advice of our legal department, in which we incorporated the following information into the template:

- The date of document creation at the end of the template to control document versions and prevent any post-approval revisions; and
- A cautionary statement requesting patients to refrain from posting on social networking service, etc.

**Drafting**

We drafted the PLS based on the Public Disclosure Synopsis as posted on the Pfizer website.6 As reference for Japanese lay language, we used informed consent documents (ICDs). A comparison of the drafting process between the previous and our current model is shown in Figure 3. In our current model, no external organisation was involved (i.e., solely authored by Pfizer Japan). Aside from paying particular attention to the above mentioned aspects of design, language and structure, and not being promotional, the draft was reviewed by in-house experts (e.g., physicians, statisticians, legal and regulatory experts) and principal investigators to ensure scientific accuracy and suitability for public disclosure. It is important to mention that we also sought feedback from a patient advocacy group that had no direct involvement with the clinical trial.

Finally, we used the following checklist of questions to ensure that the PLS was patient friendly in both format and content:

- Is it easy to understand?
- Is the language level of the content equivalent to that expected from a Japanese junior high school graduate?
- Are there arbitrary statements?
- Are there any inappropriate words?
- Can patients understand accompanying charts effectively?
- Is the text length appropriate?
- Are the font size and colour scheme appropriate?
- Are illustrations appropriate?

**Delivery to patients**

The PLS was posted on the Pfizer Japan’s website7 in PDF format and protected by a password. The link and the password were provided to the study participants at clinical trial sites.

---

Figure 1. A colour scheme comparing how people with normal vision and with colour vision abnormality perceive cold and warm colours based on Takahashi and Katayama.5 (Reprinted with permission)

- Normal vision
- Colour vision abnormality

Figure 2. Picture used in our patient lay summary. (Japanese text translation: “Dandelions spread their seeds when the wind blows. Clinical trials spread seeds of possibilities for a healthier world through your cooperation.”)
Creation of a patient-centric patient lay summary in the local language – Mogami et al.

**Figure 3. Two different processes of creating a PLS in Japan**
(PLS= patient lay summary; NPO= non-profit organisation; PDS= Public Disclosure Synopsis; PI= principal investigator)

**Previous PLS (from two other clinical trials)**
- **Source:** Results as published in Clinicaltrials.gov
- **Writing of draft & translation:** External NPO
- **Review:** In-house scientific experts
- **Distribution:** In printed form and sent from clinical trial sites

**Current PLS**
- **Source:** PDS as published on company website
- **Writing in draft:** In-house medical writers
- **Review:** In-house legal and scientific experts, PI, advocacy patient group
- **Distribution:** Posted on company website and accessible only with password

### Feedback from a patient advocacy group
Overall feedback was favourable and are summarised as follows:
- **Easy to read**
- **Very polite writing and well organised**
  (starting with the “thank you” message, then moving on to the background of the trial, the rationale for research, the method, and the results)
- **Generally, easy to understand due to the explanations provided before or after technical terms such as placebo and adverse event**
- **Warm and soft image of the dandelion suited to alleviate patients’ pains due to illness**

With these comments, it appeared that the locally developed PLS was more patient centric in language, content, and design. Using the local language from the drafting stage additionally made it easier to create a PLS that is more culturally and ethnically appropriate and thus suited the sentiment of local patients.

The previous lay summaries of the two other clinical trials, which were translated from English, were highly appreciated by patients at clinical study sites, as there had been no other attempt to provide patient access to clinical trial results. The PLS directly created in Japan received more favourable feedback because it did not only provide information but also presented the information better. In this way, the impact of PLS on patients was stronger.

We believe that enhancing patient literacy on drug development would help advance patient centricity in the pharmaceutical industry. Distributing the PLS would serve as a great opportunity to educate patients about clinical trials, helping us form a win-win relationship in drug development. In addition to giving patients access to the clinical trial results, further involvement of patient advocacy groups in preparing clinical trial related documents such as ICDs would also contribute to foster a culture of trust between pharmaceutical companies and patients. Increased transparency as regards clinical trials and their outcomes would allow us to conduct clinical trials more effectively and ultimately lead to the acceleration of drug development.

### Recommendations
Because the PLS is not a regulatory document (e.g., clinical study report) and is intended for patients, we need to be particularly careful in stating conflicts of interest and in refraining from being promotional in both content and tone. Indeed, as more steps were required to ensure the non-promotionality of a PLS, it took a longer time to finalise the PLS than any regulatory document.

To prepare a PLS more efficiently in the future, we identified a few areas that need to be improved or explored:
- **Establishment of an effective way to confirm that the PLS is not violating the promotion code**
- **Ensuring compliance with local regulations and practices**
- **Assessment of medical and statistical appropriateness in paraphrasing technical content in lay language**
- **Finding an effective way to involve principal investigators**
- **Establishing a good relationship with patient advocacy groups in Japan**
- **Increasing patient involvement in preparing the ICDs to promote patient centricity**
- **Collaboration with regulators to establish a framework for clinical trial results disclosure in the industry**
- **Improvement of medical writing skills in lay language/ local language**

We believe that industry-wide efforts are necessary to achieve these points effectively.

### Conclusions
We successfully created a PLS in the Japanese language for the first time. The locally developed PLS was more patient centric than those translated from other languages, allowing us to communicate clinical trial results in a more patient-friendly manner and helping us to form a better relationship with patients. Using the patients’ local language and being culturally sensitive are one of the most patient centric activities pharmaceutical companies can undertake.

We hope that our current attempt in developing a PLS locally would help trigger an
increase in the distribution of such summaries in Japan. We believe that locally developed summaries would bring more benefits to both patients and the pharmaceutical industry, especially in more culturally and linguistically diverse regions such as the EU.

Conflicts of interest and disclaimers
The authors are employed by Pfizer Japan Inc.

References

Author information
Satoru Mogami is the Director of Medical Writing at Pfizer Japan. He has over 20 years of experience in medical writing. He is a strong advocate for patient-centricity and a promoter of clinical trial results disclosures in the Japanese pharmaceutical industry.

Mikiko Noyes worked as a Japanese-English pharmaceutical translator before joining Pfizer. She now has over 10 years of experience in regulatory writing. Her interests include medical writing for lay audiences as well as the patient-centric document design for effective communication.

Rika Morita is a member of the Medical Writing Group at Pfizer Japan. She has over 10 years of experience in regulatory writing, with keen interest in advancing patient centricity in the pharmaceutical industry by sharing clinical trial results with participants.

Atsuko Shiotsuki is a member of the Regulatory Editing Group at Pfizer Japan. She has over 10 years of experience in regulatory writing and is a specialist in editing and publishing of investigator brochures. Her interests include delivering accurate information to patients in a timely manner.

Toshiaki Hagi has more than 20 years of experience in regulatory documentation and has been working on medical writing and editing activities for the last 18 years.

Hiroe Hasegawa has over 20 years of experience in clinical development and has been a medical writer for the past two years. She is a subject matter expert on clinical trial disclosure in Pfizer Japan and has a strong interest in increasing transparency in drug development.

Chikara Iida has over 10 years of experience in clinical development and has been with the Medical Writing Group for the past 2 years. Having worked in the development operation for many years, he is knowledgeable about interacting with patient groups and is an advocate for patient-centred drug development.

Mina Izuchi is a member of the Medical Writing Group at Pfizer Japan. She has over 10 years of experience as a regulatory writer mainly in the area of vaccines. She led the construction of the website for posting the patient lay summary.

Fumiharu Naganeo is a member of the Document Management Group at Pfizer Japan. After 4 years of medical writing experience, he now collaborates with medical writers as a regulatory dossier coordinator. He is an expert on eCTD submission and the subsequent disclosure.

Junko Tanabe has over 10 years of experience in regulatory editing and document management. Being an expert on “submission-ready” documents, she has a strong interest in “universal” document design for providing information in a patient-friendly manner.

Kyoko Uno started her career in the pharmaceutical industry in development operations. She now has over 10 years of experience in medical writing. She has extensive knowledge of submission requirements in Japan, particularly Common Technical Document (CTD) Module 1 and the public disclosure of regulatory documents.

Osamu Suga is the head of the Document Management Group at Pfizer Japan. He was a medical writer for about 16 years and was the former head of the Medical Writing Group. He led the pilot to create a patient lay summary for the first time in Japan.

Chikara Kikuchi has more than 20 years of experience in regulatory affairs and is currently the Senior Director, Regulatory Affairs, at Pfizer Japan and Vice-Chair of the Drug Evaluation Committee in the Japan Pharmaceutical Manufacturers Association.